Eupraxia Pharmaceuticals定价7000万美元

2025-09-23 14:38

Eupraxia Pharmaceuticals (NASDAQ:EPRX) priced its previously announced public offering of 12.7M common shares at a price to the public of $5.50 per common share for gross proceeds of ~$70 million.
In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 1.9M common shares on the same terms and conditions.
The offering is expected to close on September 24, 2025.
Net proceeds are expected to be used for continued advancement of its product pipeline, including the completion of ongoing preclinical studies and clinical trials, regulatory submissions, and associated commercial preparation and manufacturing scale-up activities.

More on Eupraxia Pharmaceuticals